Stubbs Alderton & Markiles, LLP announced that it represented client UCB in its launch of Nile AI, Inc. and its $29.3 million investment in the venture. Nile AI, Inc. is developing a digital epilepsy care management platform that will utilize data to make the epilepsy journey more predictable. The investment is part of UCB’s overall commitment to improving the lives of people living with severe diseases, including epilepsy, as digital technologies continue to change and impact the way healthcare is delivered. As a majority shareholder, UCB will sit on the Board of Directors of Nile with future opportunities to acquire insights and data from Nile’s platform.
To read the full press release, click here
SA&M Attorney Scott Alderton represented UCB in this transaction
Scott Alderton is a Founding Partner of the Firm, Managing Partner, and a member of the Firm’s executive committee. Scott is also Co-Chair of the Firm’s Venture Capital and Emerging Growth practice group.
Scott Alderton advises clients across a number of industries, including software, technology, digital media, interactive entertainment and video games, cyber security and life sciences.
Scott’s practice focuses on advising early stage to middle-market technology and emerging growth companies in all aspects of capital formation, venture capital and finance, corporate and securities laws, mergers and acquisitions, high technology, intellectual property, licensing, interactive entertainment and video games, the internet, digital media, manufacturing and distribution of goods in commerce and commercial contracts. Scott also regularly advises senior executive officers with respect to employment, compensation and equity incentives. Scott Alderton is frequently referenced as one of the top “start-up” lawyers in Southern California, and with over thirty years of experience working with technology and emerging growth companies at all stages along their evolutionary path, is sought out for his business as well as legal advice.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, UCB generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB).
About Nile AI, Inc.
Nile is an independent company that seeks to improve care for people living with epilepsy, their caregivers and healthcare providers. Nile is on a mission to make the journey of every epilepsy patient predictable. Its digital epilepsy care management platform will provide tools for people living with epilepsy and providers to progress to data-driven, personalized care. Nile is a collaboration-driven organization and is welcoming partners in this mission. For more information, visit www.Nile.ai and email info@Nile.ai.